Renaissance Technologies LLC increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 895,794 shares of the specialty pharmaceutical company’s stock after purchasing an additional 62,994 shares during the quarter. Renaissance Technologies LLC owned 1.49% of Jazz Pharmaceuticals worth $150,610,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. FMR LLC increased its position in shares of Jazz Pharmaceuticals by 12.1% during the 2nd quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after purchasing an additional 715,595 shares during the last quarter. BlackRock Inc. increased its position in shares of Jazz Pharmaceuticals by 2.7% during the 3rd quarter. BlackRock Inc. now owns 4,490,714 shares of the specialty pharmaceutical company’s stock worth $755,024,000 after purchasing an additional 118,634 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Jazz Pharmaceuticals by 3.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,912,173 shares of the specialty pharmaceutical company’s stock worth $321,494,000 after purchasing an additional 56,291 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Jazz Pharmaceuticals by 14.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after purchasing an additional 207,954 shares during the last quarter. Finally, Partner Fund Management L.P. increased its position in shares of Jazz Pharmaceuticals by 9.1% during the 2nd quarter. Partner Fund Management L.P. now owns 1,238,906 shares of the specialty pharmaceutical company’s stock worth $213,464,000 after purchasing an additional 103,379 shares during the last quarter. 91.53% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO Bruce C. Cozadd sold 1,300 shares of the business’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $164.36, for a total transaction of $213,668.00. Following the completion of the transaction, the chief executive officer now directly owns 281,215 shares of the company’s stock, valued at $46,220,497.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $150.00, for a total value of $105,000.00. Following the transaction, the chief financial officer now directly owns 32,068 shares of the company’s stock, valued at $4,810,200. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,600 shares of company stock valued at $1,063,472. Corporate insiders own 3.90% of the company’s stock.

A number of analysts recently issued reports on the company. BidaskClub downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Leerink Swann raised their price objective on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, August 17th. Seaport Global Securities reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 9th. HC Wainwright reissued a “hold” rating and set a $167.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 9th. Finally, Morgan Stanley set a $168.00 price objective on Jazz Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 28th. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Jazz Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $189.76.

NASDAQ JAZZ opened at $144.97 on Friday. The stock has a market capitalization of $8.73 billion, a price-to-earnings ratio of 15.16, a PEG ratio of 0.87 and a beta of 0.94. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.29 and a quick ratio of 4.16. Jazz Pharmaceuticals PLC has a 1-year low of $130.15 and a 1-year high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, beating the consensus estimate of $3.32 by $0.26. The company had revenue of $469.37 million during the quarter, compared to the consensus estimate of $482.64 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. Jazz Pharmaceuticals’s revenue was up 14.0% compared to the same quarter last year. During the same period in the previous year, the company posted $3.22 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 11.6 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Renaissance Technologies LLC Has $150.61 Million Stake in Jazz Pharmaceuticals PLC (JAZZ)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/renaissance-technologies-llc-has-150-61-million-stake-in-jazz-pharmaceuticals-plc-jazz/2668474.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Purposes and Functions of the Federal Reserve

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.